Navigation Links
Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab

immune responses. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells.

Ipilimumab is being developed through a joint partnership between Bristol-Myers Squibb and Medarex. Ipilimumab is currently in Phase III development (under Special Protocol Assessments [SPA] with the U.S. Food and Drug Administration [FDA]) to study its effects on metastatic melanoma alone and in combination with chemotherapy. Ipilimumab also is in Phase I and II development for other types of cancers, including prostate, pancreatic, bladder, lymphoma and leukemia. In December 2006, ipilimumab received Fast Track designation from the FDA for use as a monotherapy in previously treated (second-line) metastatic melanoma patients, as well as in combination with chemotherapy (dacarbazine) in previously untreated (first-line) metastatic melanoma patients. Fast Track designation was also granted for ipilimumab as a second-line treatment in combination with a melanoma-peptide vaccine.

About Melanoma

Melanoma is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) located in the skin. As with many cancers, it is more difficult to treat once the disease has spread beyond the skin to other parts of the body by way of the bloodstream or the lymphatic system (metastatic disease). Melanoma accounts for about three percent of skin cancer cases, but it causes most skin cancer deaths. The American Cancer Society estimates that in 2007 there will be 59,940 new cases of melanoma in the U.S., and about 8,110 people will die of this disease.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilit
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
6. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
7. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
9. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
Post Your Comments:
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... for cardiovascular disease and overall health is pleased to provide ... and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share with ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
...  Aria Diagnostics, a molecular diagnostics company, today announced ... examines the accuracy of its non-invasive prenatal test ... Down syndrome) and Trisomy 18 (associated with Edwards ... with a proprietary algorithm to assess individualized risk ...
... Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that ... of Gastrodia valued at 67.5 Million RMB or approximately ... Valley Pharm Corp and Sichuan Zhiyuanguanghe Pharm Corp and ... of Gastrodia from January 1, 2012 to December 31, 2012. ...
Cached Medicine Technology:Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's Technology 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 2China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*) 3
(Date:1/22/2015)... January 22, 2015 The City of West Hollywood ... a.m., to commemorate the 42nd anniversary of the Supreme Court decision ... “It’s been 42 years since the Roe vs. Wade decision and ... as present as ever,” said City of West Hollywood Councilmember Abbe ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... 30, 2011 Research in Marketing Science by ... Business, Marketing, Columbia Business School; Professor Oded Netzer, ... Business School; and Professor Ricardo Montoya, Department of ... how pharmaceutical managers can maximize the return on ...
... The use of temporary emergency department doctors and nurses poses ... study. Johns Hopkins researchers analyzed data on nearly 24,000 ... across the United States between 2000 and 2005, and found ... to be involved in medication errors that harmed patients. ...
... Nurses, just like many of their patients, struggle to ... study may give these all-important caregivers some additional pressure ... commit to a healthy lifestyle. "Nurses should model ... the study in the International Journal of Nursing ...
... It,s not how old but how frail patients are that can ... fact, young patients in poor health may have worse outcomes than ... the University of Michigan Comprehensive Cancer Center finds that patients with ... spread to distant parts of the body. These findings ...
... up to appointments with hypertension expert John Bisognano, M.D., Ph.D. ... help lower their blood pressure. And like most physicians, Bisognano ... or if they will cause any harm. "Right ... of people want to avoid standard pharmaceuticals," said Bisognano, professor ...
... used by extroverted college students and their less socially inclined ... less on partying and drinking to be happy and more ... as positive thinking. "You don,t have to go ... feel they need to do, particularly when they,re new to ...
Cached Medicine News:Health News:Research identifies marketing mix strategy for pharmaceutical firms 2Health News:Temporary ER Staff Linked to More Medication Errors 2Health News:Calling nurses to exercise as role models for their patients 2Health News:Patients' underlying health linked to worse outcomes for melanoma, U-M study finds 2Health News:Beyond pills: Cardiologists examine alternatives to halt high blood pressure 2Health News:Beyond pills: Cardiologists examine alternatives to halt high blood pressure 3Health News: Happiness: All in who you know, goals 2
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 11.1 mm x 1.5 mm x 5.7 mm....
18 gauge straight. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 27 gauge, stainless steel probes with blunt tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto th...
Straight, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tu...
Medicine Products: